New Antibody-Drug conjugate targets Hard-to-Treat cancers
NCT ID NCT06723236
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks. The main goals are to find safe doses and see if the drug can shrink or stabilize tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MGC028 (an antibody-drug conjugate targeting ADAM9)
What this could lead to
If it works, this could point toward a new treatment option for several advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 124 participants, so the drug may not prove safe or effective. Side effects could be significant, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber/Harvard Cancer Center
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
Icahn School of Medicine at Mt. Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
-
Mass General Brigham
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
-
South Texas Accelerated Research Therapeutics (START) San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
UCSF - Helen Diller Family Cancer Center
RECRUITINGSan Francisco, California, 94115, United States
Contact